Immunome (IMNM) analyst forecast and price target
Analyst forecast
Consensus of 14 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $35.00 from $31.00 | Aug 12, 2026 |
| Truist Securities | Maintained | Buy | $38.00 from $37.00 | Aug 12, 2026 |
| Wedbush | Maintained | Outperform | $31.00 | Jul 21, 2026 |
| Wedbush | Maintained | Outperform | $31.00 | Jun 12, 2026 |
| Truist Securities | Maintained | Buy | $37.00 from $36.00 | May 28, 2026 |
| Barclays | Initiated Coverage | Overweight | $36.00 | May 28, 2026 |
| Leerink Partners | Maintained | Outperform | $33.00 from $37.00 | May 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $40.00 | May 13, 2026 |
| Stephens & Co. | Maintained | Overweight | $30.00 from $33.00 | Mar 4, 2026 |
| Craig-Hallum | Maintained | Buy | $36.00 from $33.00 | Mar 4, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $40.00 | Feb 12, 2026 |
| Wedbush | Maintained | Outperform | $31.00 | Jan 15, 2026 |
| Evercore ISI Group | Maintained | Outperform | $40.00 from $18.00 | Dec 16, 2025 |
| Lake Street | Maintained | Buy | $32.00 from $22.00 | Dec 16, 2025 |
| Guggenheim | Maintained | Buy | $35.00 from $25.00 | Dec 16, 2025 |
| Truist Securities | Initiated Coverage | Buy | $36.00 | Dec 1, 2025 |
| Stephens & Co. | Maintained | Overweight | $33.00 from $25.00 | Nov 17, 2025 |
| Goldman Sachs | Initiated Coverage | Buy | $26.00 | Sep 22, 2025 |
| Craig-Hallum | Initiated Coverage | Buy | $26.00 | Sep 5, 2025 |
| Guggenheim | Maintained | Buy | $25.00 | Aug 25, 2025 |
Frequently asked questions
Is IMNM a buy, sell, or hold?
Analysts covering Immunome currently average a Buy rating: 14 buy, 0 hold and 0 sell, from 14 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on IMNM?
On Aug 12, 2026, Wedbush maintained Immunome at Outperform with a price target of $35.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.